How do I subscribe to ongoing alerts?

Subscribe to /feed/company/fundaci-n-p-blica-andaluza-para-la-gesti-n-de-la-investigaci-n-en-sevilla.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla pipeline: 5 marketed, 0 filed, 5 Phase 3, 7 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 5 Phase 3 7 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Fludeoxyglucose 18F	Fludeoxyglucose 18F	marketed			Metabolic
PEG-3350 with electrolytes	PEG-3350 with electrolytes	marketed
Empirical antimicrobial treatment discontinuation	Empirical antimicrobial treatment discontinuation	marketed
Polyethylene Glycol 4000 with electrolytes	Polyethylene Glycol 4000 with electrolytes	marketed	Osmotic laxative		Gastroenterology
Standard empirical antimicrobial treatment discontinuation	Standard empirical antimicrobial treatment discontinuation	marketed			Infectious Disease / Antimicrobial Stewardship
Ceftriaxone intravenous	Ceftriaxone intravenous	phase 3	Third-generation cephalosporin	Penicillin-binding proteins (PBPs)	Infectious Disease
romiplostim plus dexamethasone	romiplostim plus dexamethasone	phase 3	Thrombopoietin receptor agonist plus corticosteroid	Thrombopoietin receptor (TPO-R); glucocorticoid receptor	Hematology/Immunology
Fosfomycin sodium intravenous	Fosfomycin sodium intravenous	phase 3	Cell wall synthesis inhibitor	MurA (UDP-N-acetylglucosamine enolpyruvyl transferase)	Infectious Disease
Meropenem intravenous	Meropenem intravenous	phase 3	Carbapenem antibiotic	Penicillin-binding proteins (PBPs)	Infectious Disease
Antipseudomonal beta-lactam antibiotic	Antipseudomonal beta-lactam antibiotic	phase 3	Antipseudomonal beta-lactam antibiotic	Penicillin-binding proteins (PBPs)	Infectious Disease

Therapeutic area mix

Infectious Disease · 4
Gastroenterology · 1
Hematology/Immunology · 1
Infectious Disease / Antimicrobial Stewardship · 1
Metabolic · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Bayer · 2 shared drug classes
Ahmed M Maged, MD · 1 shared drug class
Amsterdam UMC, location VUmc · 1 shared drug class
Assistance Publique - Hôpitaux de Paris · 1 shared drug class
Azienda Policlinico Umberto I · 1 shared drug class
Aboca Spa Societa' Agricola · 1 shared drug class
Benaroya Research Institute · 1 shared drug class
Abbott · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Fundación Pública Andaluza para la gestión de la Investigación en Sevilla:

Cite this brief

Drug Landscape (2026). Fundación Pública Andaluza para la gestión de la Investigación en Sevilla — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fundaci-n-p-blica-andaluza-para-la-gesti-n-de-la-investigaci-n-en-sevilla. Accessed 2026-05-17.